# Effect of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation

> **NCT03542721** · PHASE4 · UNKNOWN · sponsor: **Dong-A Pharmaceutical** · enrollment: 204 (estimated)

## Conditions studied

- Fatigue Symptom

## Interventions

- **DRUG:** DA-5515
- **DRUG:** Placebo of DA-5515

## Key facts

- **NCT ID:** NCT03542721
- **Lead sponsor:** Dong-A Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-17
- **Primary completion:** 2019-06
- **Final completion:** 2019-12
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2018-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03542721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03542721, "Effect of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03542721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*